Trials / Completed
CompletedNCT00546676
Ketek in CAP / AECB in Ambulatory Adult Patients
A Canadian Multicenter, Prospective, Open Label, Non-Comparative Study of the Effectiveness and Safety of Oral Telithromycin, 800mg Once Daily in the Treatment of Either Community Acquired Pneumonia or Acute Exacerbation of Chronic Bronchitis in Ambulator
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 174 (actual)
- Sponsor
- Sanofi · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
To determine the clinical effectiveness of telithromycin in the treatment of either CAP or AECB in a large population of ambulatory adult patients in a community-based setting.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Telithromycin |
Timeline
- Start date
- 2004-05-01
- Completion
- 2004-12-01
- First posted
- 2007-10-19
- Last updated
- 2007-11-14
Source: ClinicalTrials.gov record NCT00546676. Inclusion in this directory is not an endorsement.